Epitracker is advancing anti-aging products across four discovery & development programs:
- Cardiometabolic diseases. Our lead lipid-based compound, ETI-101, has demonstrated in vivo efficacy in lowering insulin, glucose, cholesterol, and inflammation. Series A funding will be used to advance an optimized ETI-101 from preclinical studies through FDA IND approval.
- Senescence. We have discovered molecules that appear to preserve the integrity of cell membranes, which can delay premature cell death, a cornerstone of aging. Proof of concept studies are in progress, and we anticipate lead compound identification and optimization during 2018.
- Dementia. We are discovering molecules that may reduce neuroinflammation and neuronal iron deposition, both of which may prevent or stop the progression of dementia, including Alzheimer's disease. Proof of concept studies are anticipated during 2019.
- Skin repair. We will be launching discovery of lead compounds during late 2018 or early 2019 to identify molecules that can improve wound healing and preserve the integrity of young, healthy skin.
Epitracker Patent Portfolio
Epitracker's anti-aging platform is being developed as part of an exclusive license with the U.S. Navy to commercialize products under five issued and nine pending U.S. and international patents (Space and Naval Warfare Systems Center Pacific Agreement Number PLA-SSCPacific-15-002).
ETI-101 for Metabolic Syndrome
ETI-101 (EpitRx), Epiracker's lead lipid-based oral therapeutic, is being developed to treat metabolic syndrome, a disease affecting 1 in 4 people globally. Early studies suggest that ETI-101 provides broad cardiometabolic and anti-aging benefits, including lowered glucose, insulin, cholesterol and inflammation. ETI-101 has high bioavailability, a strong safety profile, and known mechanism of action. An optimized ETI-101 will enter preclinical studies toward FDA's Investigational New Drug (IND) approval.
There is currently no single drug to treat metabolic syndrome, a disease affecting 1 in 4 people globally. Currently, people are prescribed different drugs for each of metabolic syndrome's components. This may include glitazones for insulin resistance, metformin for high glucose, fibrates for high triglycerides, and ACE inhibitors of high blood pressure. Current research with ETI-101 suggests that it may help treat early, upstream causes of metabolic syndrome and aging-associated conditions, potentially negating the need to treat its downstream components.